External validation of FibroIndex.

Halfon P, Penaranda G, Renou C, Bourliere M

MeSH — NLM indexing Biomarkers / blood Hepatitis C, Chronic / complications Hepatitis C, Chronic / diagnosis Hepatitis C, Chronic / pathology Humans Liver Cirrhosis / blood Liver Cirrhosis / diagnosis Liver Cirrhosis / pathology Models, Biological Predictive Value of Tests

Altre di Halfon P

Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.

Antivir Ther · 2009

FibroTest-ActiTest as a non-invasive marker of liver fibrosis.

Gastroenterol Clin Biol · 2008

Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.

J Hepatol · 2007

Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.

Am J Gastroenterol · 2006

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.

Comp Hepatol · 2002

Altro sullo stesso argomento

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Biomedicines · 2025

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

World J Hepatol · 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Cardiovasc Diabetol · 2025

Noninvasive Assessment of Liver Fibrosis.

N Engl J Med · 2025

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Diabetes Care · 2025

Toward non-invasive assessment strategies in autoimmune hepatitis.

World J Hepatol · 2025